Physician profile
Veronica Torres
NPI 1376171074
$4,943.43
in general payments reported to CMS, 2019-2025
27 companies · $24.47 in 2025
The $24.47 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $637 · 2022: $2,042 · 2023: $2,189 · 2024: $50.33 · 2025: $24.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,221 · Education: $42.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,221.25 |
| Education | $42.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,270.59 | 2021-2023 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $982.56 | 2021-2023 | |
| Lilly USA, LLC | $537.29 | 2021-2023 | Taltz |
| Janssen Biotech, INC. | $455.30 | 2022-2023 | Simponi Aria, Tremfya, Remicade |
| Glaxosmithkline, LLC. | $373.22 | 2021-2023 | Benlysta |
| Ucb, INC. | $275.50 | 2021-2023 | Cimzia |
| Astrazeneca Pharmaceuticals Lp | $140.90 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.24 | 2022-2023 | Cyltezo, Ofev |
| Novartis Pharmaceuticals Corporation | $97.10 | 2023 | |
| Indivior INC. | $83.41 | 2023-2024 | Perseris |
| Aurinia Pharma U.S., INC. | $70.33 | 2022-2023 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $64.70 | 2023 | Orencia |
| Pfizer INC. | $61.64 | 2022-2023 | |
| Horizon Therapeutics Plc | $43.88 | 2022 | |
| Celltrion USA INC. | $42.37 | 2023 | Yuflyma |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $40.31 | 2023 | Idacio |
| Sandoz INC. | $37.52 | 2023 | Hyrimoz |
| Almatica Pharma LLC | $35.72 | 2022 | |
| Organon LLC | $35.61 | 2023-2024 | Renflexis |
| Janssen Pharmaceuticals, INC | $32.33 | 2021 | |
| Octapharma USA, INC. | $32.05 | 2023 | Octagam Immune Globulin (Human) |
| Boston Scientific Corporation | $24.47 | 2025 | General - Pain Management |
| Medtronic, INC. | $23.14 | 2023 | Intellis Adaptivestim |
| Genentech USA, INC. | $22.91 | 2024 | Phesgo |
| Radius Health, INC. | $22.57 | 2023 | Tymlos |
| Mallinckrodt Hospital Products INC. | $17.30 | 2022 | |
| Alkermes, INC. | $13.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.